Suppr超能文献

镰状细胞病的基因治疗:我们现在在哪里?

Gene therapy for sickle cell disease: where we are now?

机构信息

Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.

Department of Pediatrics, Ochsner Hospital for Children, Jefferson, LA.

出版信息

Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):174-180. doi: 10.1182/hematology.2021000250.

Abstract

The landscape of sickle cell disease (SCD) treatment continues to evolve rapidly, with new disease-modifying therapies in development and potentially curative options on the horizon. Until recently, allogeneic stem cell transplant has been the only proven cure for SCD. Gene therapy is rising to the forefront of the discussion as a potentially curative or highly disease- modifying option for abating the complications of the disease. Understanding the different types of gene therapy in use, the differences in their end points, and their potential risks and benefits will be key to optimizing the long-term use of this therapy.

摘要

镰状细胞病(SCD)的治疗领域正在迅速发展,新的疾病修饰疗法正在开发中,潜在的治愈方法也即将出现。直到最近,异基因造血干细胞移植一直是 SCD 唯一被证实的治愈方法。基因疗法作为一种潜在的治愈或高度疾病修饰方法,正在成为治疗疾病并发症的讨论热点。了解正在使用的不同类型的基因疗法、它们终点的差异以及它们的潜在风险和益处,将是优化这种疗法长期使用的关键。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/538c/8791177/9f33d8d2972b/hem.2021000250_s1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验